Source:http://linkedlifedata.com/resource/pubmed/id/18782289
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2008-10-17
|
pubmed:abstractText |
The significance of B-cell crossmatching in kidney transplantation is controversial. Recipients (n = 471) transplanted in a single centre from 1987 to 2005 with complete T- and B-cell crossmatch records were studied. Sera from 83 patients transplanted across a positive B-cell crossmatch, with concomitant negative T-cell crossmatch (T-B+) on either current and/or peak sera were studied using Luminex to determine presence of donor-specific antibodies (DSA). Clinical outcomes of T-B+ patients were compared with 386 T-B- patients. T-B+ predicted vascular (p = 0.01), but not cellular (p = 0.82) or glomerular (p = 0.14) rejection. IgG HLA DSA were found in 33% (n = 27) of the T-B+ patients and were associated with higher risk of any (p = 0.047), vascular (p = 0.01) or glomerular (p < 0.001) rejection at 6 months. Of 27 patients with DSA, 18/21 (86%) were the complement-fixing IgG(1) and/or IgG(3) subclass antibodies. DSA imposed a statistically significant higher risk of graft loss 5 years posttransplant (1.8 [1.0-3.3], p = 0.045). This study showed that only one-third of positive B-cell crossmatch (BXM) was caused by DSA and was associated with late graft loss. Thus, using BXM to preclude kidney transplantation may potentially disadvantage >60% of patients in whom BXM is not indicative of the presence of DSA.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1600-6143
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2335-42
|
pubmed:meshHeading |
pubmed-meshheading:18782289-Antibody Specificity,
pubmed-meshheading:18782289-Antilymphocyte Serum,
pubmed-meshheading:18782289-Autoantibodies,
pubmed-meshheading:18782289-B-Lymphocytes,
pubmed-meshheading:18782289-Glomerular Filtration Rate,
pubmed-meshheading:18782289-Graft Rejection,
pubmed-meshheading:18782289-Graft Survival,
pubmed-meshheading:18782289-HLA Antigens,
pubmed-meshheading:18782289-Histocompatibility Antigens Class I,
pubmed-meshheading:18782289-Histocompatibility Antigens Class II,
pubmed-meshheading:18782289-Histocompatibility Testing,
pubmed-meshheading:18782289-Humans,
pubmed-meshheading:18782289-Immunophenotyping,
pubmed-meshheading:18782289-Kidney Transplantation,
pubmed-meshheading:18782289-T-Lymphocytes
|
pubmed:year |
2008
|
pubmed:articleTitle |
Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss.
|
pubmed:affiliation |
Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|